

Dec 25, 2018

SENJU PHARMACEUTICAL CO.,LTD

Launch of Neuroptika, Inc.

Senju Pharmaceutical Co., Ltd. (Osaka, Japan) announced the launch of Neuroptika, Inc. (Cambridge, Boston, CEO: Hyunsuk Timothy Min, M.A., J.D.), a spin out from Senju. Neuroptika, Inc. will be focused on the development of SI-01, a novel therapeutic drug that protects and regenerates corneal nerves in ophthalmic diseases.

The lead compound for Neuroptika, Inc., SI-01, has demonstrated accelerated nerve regeneration and led to the recovery of functional nerves and corneal sensitivity in an animal model with nerve impairment. SI-01 is currently in a Phase 1 study with plans to advance to Phase 2 studies in patients with dry-eye disease and those needing post-LASIK care.

[Contact details for inquiries]

Neuroptika, Inc.

1770 Massachusetts Ave, Suite 163 Cambridge, MA 02140

hyunsuk.min@neuroptika.com